knowledge -WSS

knowledge

author：fashion 2025-08-12 08:25:20 - browse：89

Under the Affordable Care Act, health insurers are required to cover all costs associated with preventive care — including PrEP, or pre-exposure prophylactic treatment for HIV. But now all preventive care coverage is under threat, thanks to a lawsuit filed by employers who believe they shouldn’t be required to pay for care that violates their religious beliefs.

While coverage for PrEP access is largely unchanged as the court case makes its way through the legal system, Richard Hughes IV, a partner with the law firm Epstein Becker Green, says that protecting the status quo isn’t enough. For instance, currently you have to jump through extra hoops to get long-acting injectable PrEP covered by insurance.

But Hughes has a better idea for how to not only protect but also expand access to PrEP.

On this episode of the “First Opinion Podcast,” I spoke to Hughes about his proposal, why access to PrEP has never been what it should be, the Supreme Court’s current approach to health care, and more.

“If a provider has a bad experience with a previous patient experiencing non-coverage, they might say to the next patient, ‘Well, I’m not sure this is going to be covered.’ And that can be really discouraging,” Hughes said. “What we really need to create that clarity for patients is for this law to be upheld, for the recommendations to be clear, and for providers to have the assurance that they will be covered by payers.”

Our conversation was based on his recent First Opinion op-ed, “How to protect PrEP coverage, no matter what happens in Braidwood v. Becerra.”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

And if you have any feedback for us — First Opinion authors to feature on the podcast, kudos, or darts — email us at [email protected] and please put “podcast” in the subject line.

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Surgery pushed Ben Carson to fame

WSS

Devoted Health’s losses in Medicare Advantage persist

Devoted Health’s losses in Medicare Advantage persist

Eli Lilly to pay $200M for Beam’s stake in gene

Meta's Zuckerberg and Chan on track to put $50 billion into science

Readout Newsletter: Amgen, Regeneron, BGI Group and more

FDA has safety concerns on CRISPR

knowledge

knowledge

knowledge

Alkermes shareholders re

Meta's Zuckerberg and Chan on track to put $50 billion into science

Walensky prepares to leave CDC — and Congress — behind

Top private equity targets in 2023: cardiology, clinical trials, lasers

Medical leaders decry Supreme Court decision on affirmative action

The FDA weighs the risks of candy

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: What happened with Sarepta's Duchenne data

After affirmative action ruling, medical educators look to 'holistic review'

What’s missing from the debate over nursing home staff minimums

focus

Why Novartis is going to walk from its acquisition of MorphoSys

Readout Newsletter: What happened with Sarepta's Duchenne data

Readout Newsletter: XBI biotech index, Akero Therapeutics

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Why Novartis is going to walk from its acquisition of MorphoSys

WHO may add ‘noma' to its list of neglected tropical diseases

focus

focus

knowledge

hotspot